Please assess the completion status of the following clinical trial:

Trial Title: Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the SCYX-7158

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male healthy volunteers 18 to 45 years of age,~* All subjects to be of sub-Saharan African origins with both parents of Sub-Saharan African origins too,~* Male subjects with a body mass index (BMI) calculated as weight in kg/(height in m2) from 18 to 28 kg/m2 at screening,~* Able to communicate well with the Investigator and research staff and to comply with the requirements of the entire study,~* Provision of written informed consent to participate as shown by a signature on the volunteer consent form,~* Light smokers (less than 5 cigarettes per day) or subjects who are non-smokers. No smoking (or use of smoking substitute e.g. nicotine patch) is permitted from screening throughout the study,~* Normal arterial blood pressure (BP) and pulse rate or, if abnormal, considered not clinically significant by the principal Investigator. These will be measured after resting for 5 min.~* Registered with the French Social Security in agreement with the French law on biomedical experimentation.~Exclusion Criteria:~* Who on direct questioning and physical examination have evidence of any clinically significant acute or chronic disease, including known or suspected HIV, HBV or HCV infection,~* Who previously received SCYX-7158,~* Who presented acute or chronic or history of symptoms of Gastro intestinal disturbances (GI) or on physical examination have evidence of any clinical signs of acute or chronic GI abnormality ( i.e hemorrhoids, GI bleeding...)~* With any clinically significant abnormality following review of pre-study laboratory tests (aspartate aminotransferase (ASAT) and alanine aminotransferase (ALAT) must be within normal ranges), vital signs, full physical examination and ECG,~* Who are within the exclusion period defined in the National Register for Healthy Volunteers of the French Ministry of Health,~* Who forfeit their freedom by administrative or legal award or who were under guardianship,~* Unwilling to give their informed consent,~* Who have a positive laboratory test for Hepatitis B surface antigen (HbsAg), or anti-HIV 1/2 or anti- HCV antibodies~* Who have a history of allergy, intolerance or photosensitivity to any drug,~* Who have a history of serious allergy, asthma, allergic skin rash or sensitivity to any drug,~* Who are known or suspected alcohol or drug abusers (more than 14 units of alcohol per week, one unit = 8 g or about 10 mL of pure alcohol),~* Who drink more than 8 cups daily of beverage containing caffeine,~* Who have a positive laboratory test for urine drug screening (opiates, cocaine, amphetamine, cannabis, benzodiazepines),~* Who have undergone surgery or have donated blood within 12 weeks prior to the start of the study,~* Who have taken any prescribed or over the counter drug (including antacid drug), with the exception of paracetamol (up to 3 g per day) within 2 weeks prior to the first dose administration,~* Who have any clinical condition or prior therapy which, in the opinion of the Investigator, made the subject unsuitable for the study,~* Who participated to any clinical trial with an investigational drug in the past 3 months preceding study entry.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- SCYX-7158 (Type: EXPERIMENTAL): In each dose group (8 subjects) , 6 Healthy Volunteers receive SCYX-7158
- Placebo of SCYX-7158 (Type: PLACEBO_COMPARATOR): In each dose group (8 subjects) , 2 Healthy Volunteers receive placebo of SCYX-7158

Based on this trial design, predict the completion outcome and termination type (if applicable).